

Cambridge University Press

978-1-107-03323-8 - A Concise Guide to Understanding Suicide: Epidemiology, Pathophysiology, and Prevention

Edited by Stephen H. Koslow, Pedro Ruiz and Charles B. Nemeroff

Index

[More information](#)

# Index

Note: page numbers in *italics* refer to figures; those with suffix 'n' refer to notes

- acculturation 63
- ACPI gene 283
- acquired capability for suicide (ACS) in
  - eating disorders 125–127
- adenylyl cyclase-cAMP signaling system 344, 345, 348
- adolescents 151–157
  - age at suicide 151
  - borderline personality disorder 111–112
  - bullying 166–171
  - depression treatment 155
  - developmental group therapy 155
  - epidemiology of suicide 151–152
  - ethnicity 151
  - family process treatments 155–156
  - fMRI in suicidal behavior 310
  - indigenous populations 159–160, 161
  - interventions 155–156
  - PKA changes in brain 348–349
  - psychiatric disorders 153–154
  - psychological factors 154
  - psychosocial factors 154–155
  - risk factors 152–155
  - sex 151
  - social process treatment 155–156
  - substance use disorders 118
  - suicidal behaviors 240–241, 241
  - suicidal ideation 152–153
  - suicide rate 79, 152
  - trends in 152, 153
  - venlafaxine and suicidal risk 240–241
  - see also* youths/young adults
- adrenergic receptors 327–328
- adrenocorticotrophic hormone (ACTH) 290
  - levels following early life adversity 290
- adverse events
  - national rates 76–77
  - rare 76–77
- African American males 63, 64
- alpha<sub>1</sub> adrenergic receptors 327–328
- alpha<sub>2</sub> adrenergic receptor(s) 328
  - genetic polymorphisms 328
- alpha<sub>2</sub> adrenergic receptor
  - antagonists 330
- alternative psychopathology, epilepsy 132–133
- gamma-aminobutyric acid (GABA)
  - see* GABA
- ancient Egypt 3
- ancient Greece 3, 4
- ancient Rome 4
- anorexia nervosa (AN) 123
  - fatal suicide attempts 124
  - low belongingness 126–127
  - non-fatal suicide attempts 124
  - postmortem studies 125
  - subtypes 123
  - suicidal ideation 123–124
- anterior cingulate gyrus in borderline personality disorder 111
- anticonvulsants
  - mood-stabilizing 222
  - see also* antiepileptic drugs (AEDs)
- antidepressants 74, 237–242
  - adverse effects 217–218
  - BDNF promoter effects 294
  - bipolar disorder 217–218
  - black box warning 237–238, 363
  - changes following 77
  - unintended consequences 238, 239
- bupropion 241
- county-level analysis 77
- cumulative sum method 75
- ecological methods for rare adverse events 76–77
- empirical Bayes screening 75
- glial function targeting 332
- locus coeruleus effects 332–333
- meta-analysis of RCTs 77–80
- mirtazapine 241
- monoamine oxidase inhibitors 242
  - norepinephrine signaling manipulation 329
- non-proportional hazards for suicide attempts 82
- norepinephrine signaling
  - manipulation 328–331
- person-time logistic regression
  - models 82–83
- Poisson method 75
- post-receptor signaling 333–334
- prevention of suicide 362–363
- proportional reporting ratio 74–75
- protective role 237, 238
- spontaneous reports 74–76
- suicidal ideation 238, 239
- suicidality association 237
- suicide rate 87
  - national 76–77
- suicide risk 97, 240–241
  - children/adolescents 240–241
- symptom control 97
- tricyclic antidepressants 241–242
  - norepinephrine signaling manipulation 329
- tyrosine hydroxylase expression reduction 326
- see also* selective serotonin reuptake inhibitors (SSRIs); serotonin norepinephrine reuptake inhibitors (SNRIs)
- antiepileptic drugs (AEDs) 130
  - suicide risk 133–134, 203
- antipsychotic medication
  - atypical in norepinephrine signaling manipulation 330–331
- clozapine 229–234
- extrapyramidal side effects 230
- suicide rate 87, 222
- antisocial personality disorder (APD) 112–113
- anxiety 93–98
  - armed forces 191–194
  - bipolar disorder association 94
  - comorbid personality disorders 97
  - depression association 94
  - suicide risk 90
  - in epilepsy 132
- aripiprazole 330
- armed forces 191–198
  - anxiety 191–194
  - continuity of care 197
  - cultural factors 195
  - depression 191–194
  - epidemiology of suicide 191–193
  - help seeking 196–197
  - mental health
    - care 197
    - surveillance 193
  - mental illness 194, 196
  - method of suicide 192
  - overseas deployment 195
  - post-traumatic stress disorder 191–194

## Index

- armed forces (cont.)
  - pre-enlistment suicidal history 192–193
  - prevention of suicide 195–196
  - protective factors 195
  - return from deployment 194
  - screening 193
  - social support 195
  - stigma 196–197
  - stress 194–195
  - suicidal ideation 191
  - suicide attempts 191
  - suicide rate 191, 192
  - suicide risk factors 193–195
  - surveillance 193
  - traumatic brain injury 194
  - treatment 196–197
  - unit cohesion 195
  - weapons management 197
- astrocytes 331–332
- attachment theory 67–68
  - complicated grief 71
- attachment-based family therapy (ABFT) 156
- attentional fixation 44
- atypical antipsychotics 330–331
- audience reception studies of media influence 378, 379
- Bayes estimate of suicide rate 75, 78
- belongingness
  - low in eating disorders 126–127
  - thwarted 256–257
- bereavement
  - Bowlby's ideas 67–68
  - complicated grief 69
  - coping strategy 70
  - definitions 66–67
  - framework 67–68
  - grief association 69–70
  - model 69
  - postvention 70–71
  - suicide-related 66–68
  - support strategies 70–71
- beta-adrenergic receptors 328
- between-subject designs 81
- binge-eating disorder (BED) 123
  - fatal suicide attempts 124–125
  - non-fatal suicide attempts 124
  - perceived burdensomeness 126
  - suicidal ideation 123–124
- binge-eating/purging subtype anorexia nervosa (BPAN) 123
- bipolar disorder 62–63
  - antidepressant treatment 217–218
  - anxiety association 94
  - fMRI in suicidal behavior 310
  - follow-up care 363
  - index of lethality 219
  - lithium treatment 217–225
    - evidence for 218–219
    - patient monitoring 224
    - study limitations 224
    - suicide risk meta-analysis 219, 220
  - morbidity types 218
  - mortality 217
  - risk factors 95
  - screening for in depression 358
  - suicidality measure 283
  - suicide attempt 217
  - suicide rate 217
  - suicide risk 219
    - update of meta-analysis 220–221
  - treatment 217–225, 362–363
- black box warning for antidepressants 237–238, 363
  - changes following 77
  - unintended consequences 238, 239
- borderline personality disorder (BPD) 110
  - adolescents 111–112
  - anterior cingulate gyrus volume reduction 111
  - characteristic-associated suicide 110–111
  - comorbidities 110
  - lithium treatment 221
  - neurobiological underpinnings 111
  - non-suicidal self-injury
    - association 111
  - opioid deficit 111
  - structural brain alterations 309
  - treatment 112
- brain
  - anterior cingulate gyrus in borderline personality disorder 111
  - corpus callosum in major depressive disorder 308–309
  - corticoid receptors 340
  - CRF
    - function 340–341
    - levels 341
  - CRF-R1 and CRF-R2 expression 339
  - dorsal raphe nucleus 317, 318–319
    - neuroanatomy 318–319, 319
    - serotonin indices alterations in depressed suicides 320
    - TPH2 levels 321, 322
  - fronto-striatal network in major depressive disorder 307–309
  - 5-HT levels
    - brainstem 323
    - psychological autopsy 317–322
  - median raphe nucleus 317, 318, 319
  - anatomy 319
  - paraventricular nucleus of hypothalamus 292–293
  - prefrontal cortex in major depressive disorder 308
- regulation in early life 288–290
- structural alterations
  - in borderline personality disorder 111, 309
  - in major depressive disorder 307–309
  - in schizophrenia 309
  - see also* hippocampus; locus coeruleus (LC); neuroimaging
- brain-derived neurotrophic factor (BDNF) 96, 350–351, 353
  - blood cell levels 350–351
  - brain levels 350
  - functions 350
- brain-derived neurotrophic factor (BDNF) gene 293–294
- imipramine effect on transcription 294
- methylation state 294
- PTSD rat model 294
- breastfeeding 144–145
- bulimia nervosa (BN) 123
  - fatal suicide attempts 124
  - low belongingness 126–127
  - non-fatal suicide attempts 124
  - suicidal ideation 123–124
- bullying 166–171
  - age 170
  - bystander role 168
  - complexity of relationship with suicide 166–167
  - correlational studies 167–168
  - cyberbullying 169–170
  - depression association 167, 168
  - duration 170
  - evidence-based interventions 170–171
  - frequency 170
  - incidence 166
  - long-term consequences 168–169
  - outcomes 170
  - perpetrators 166, 168
    - depression association 167
  - research
    - future 170–171
    - methodology 170
  - suicidal behaviors 167–168
  - suicidal ideation 166, 167–168, 169
  - suicide attempts 166, 167–168
  - suicide risk factors 166
  - victimization 168–169
- bupropion 241
- burdensomeness, perceived 256–257
  - eating disorders 126
- calcium channel genes 284
- cancer
  - suicidal ideation 205
  - suicide risk 204–205
- capacity in suicide risk assessment 252
- case-control studies 80

## Index

- celebrity suicides
  - suicide cluster effects 54, 56–57
  - suicide contagion effects 58
- child abuse, physical/sexual 288
  - glucocorticoid receptor levels 340
- children 151–157
  - age at suicide 151
  - bullying 166–171
  - depression treatment 155
  - developmental group therapy 155
  - early life adversity, burden 288–290
  - epidemiology of suicide 151–152
  - ethnicity 151
  - family process treatments 155–156
  - interventions 155–156
  - psychiatric disorders 153–154
  - psychological factors 154
  - psychosocial factors 154–155
  - risk factors 152–155
  - sex 151
  - social process treatment 155–156
  - suicidal behaviors 240–241, 241
  - suicidal ideation 152–153
  - suicide rate 79, 152
    - trends in 152, 153
  - venlafaxine and suicidal risk 240–241
  - see also* youths/young adults
- cholesterol levels 96
- Christianity 3, 5
- chromatin 289, 292
- chronic obstructive pulmonary disease (COPD) 202
- cigarette smoking 321–322, 323
- citalopram 239
- clozapine 105–106, 229–234, 330
  - adverse effects 232–233
  - agranulocytosis monitoring 231, 232, 233
  - prevention of suicide 363
- schizophrenia treatment 229
  - dosage 234
  - drug interactions 234
  - FDA approval 231–232
  - outcomes 233
  - smoking cessation 234
  - suicide risk 230–232
  - suicide risk reduction guidelines 233–234
  - underutilization 232–233
- cognitive behavioral model of suicidality 309–310, 309
- cognitive behavioral techniques 257–269
- cognitive behavioral therapy (CBT) 363
  - general 268–269
  - integrated 156
  - psychosocial approaches to
    - reduce suicidal behavior 257, 268–269, 271
  - schizophrenia 106
- cognitive impairment, schizophrenia 103–104
- cognitive model of suicidal behavior 256
- cognitive rigidity 47
- coherence 84
- cohort studies 80
- Collaborative Assessment and Management of Suicidality (CAMS) 367
- college students 173–180
  - campus education/training 179
  - campus living 177–178
  - commuters 176
  - depression 175
  - epidemiology of suicide 173–174
  - gay, lesbian, bisexual, and transgender students 176–177
  - groups 175–177
  - impulsivity 177
  - international students 176
  - legal cases for institutional liability 178
  - life transition 174–175
  - means of suicide restriction 179
  - medical students 176
  - mental illness 173–174
  - older 176
  - prevention strategies 177–180
    - elements 179
    - programing 179–180
  - protective factors 177
  - reason for living 177
  - resources 175–177
  - screening for suicide risk 174, 179
  - social support 177
  - substance abuse 175
  - suicidal behaviors 173
  - suicide rate 173
  - suicide risk assessment 178, 179
  - suicide risk factors 174–177
- command hallucinations 102
- community-engaged approaches
  - indigenous populations 162–163
  - process for suicide prevention 163
- comorbidity
  - older adults 185
  - schizophrenia with substance abuse 103
- complicated grief treatment (CGT) 71, 71
- confidentiality, risk assessment in
  - emergency room 253
- contact interventions 270–271
- content analysis studies of media
  - influence 378–379
- coronary heart disease (CHD) 202
- corpus callosum, major depressive disorder association 308–309
- correctional facilities 208–215
  - causes of death 209
  - characteristics of suicides 209–212
  - conditions in 208–209
- incarceration impact 210
  - interventions 212–215
- mental health care requirements 209
- method of suicide 210
- multidisciplinary morbidity/mortality reviews 215
- observation 214
- physical environment 210, 214
- population 210
- precautions 212–215
- privileges/property 214
- psychosocial factors 210
- risk factors 209–210
- screening 213
- single cell housing 210, 214
- staff 214–215
- stress of incarceration 210
- suicide rates 209–212
- suicide risk
  - monitoring 213–214
  - profile 212–213
  - screening 213
- corticoid receptors 340
- corticotropin-releasing factor (CRF)
  - 95, 290, 336–341
  - action on HPA axis 338
  - function 336, 340–341
  - levels
    - in brain 341
    - in CNS 336
  - role in suicide 338–339
- corticotropin-releasing factor binding protein (CRF-BP) 339–340
- HPA axis role 339–340
- corticotropin-releasing factor (CRF) gene 293
- corticotropin-releasing factor receptor
  - 1 (CRF-R1)
    - expression in brain 339
    - genetics 339
    - role in suicide 338–339
- corticotropin-releasing factor receptor
  - 2 (CRF-R2)
    - expression in brain 339
    - role in suicide 338–339
- cortisol 290
  - levels following early life
    - adversity 290
- CpG islands 289
- CpG methylation 291
- CREB signaling 349–350
- criminal justice system *see* correctional facilities
- crisis response plan 367
- crisis safety planning 120
- cultural factors 62–64
  - armed forces 195
  - children 151
  - indigenous populations 160, 161
  - mental illness 62–63

Cambridge University Press

978-1-107-03323-8 - A Concise Guide to Understanding Suicide: Epidemiology, Pathophysiology, and Prevention

Edited by Stephen H. Koslow, Pedro Ruiz and Charles B. Nemeroff

Index

[More information](#)

## Index

- cultural factors (cont.)
  - predominant influence 63–64
  - youths 151
- cultural-bound syndrome 62
- cumulative sum (CUSUM) method 75
- cyberbullying 169–170
- dementia
  - older adults 184–185
  - suicide risk 202–203
- depression 62, 63, 93–98
  - $\alpha_1$  adrenergic receptors 327–328
  - anxiety association 94
  - armed forces 191–194
  - bipolar disorder screening 358
  - bullying association 167, 168
  - college students 175
  - comorbid personality disorders 97
  - epigenetic components in
    - stress-induced animal models 298
  - fMRI 310–311
  - follow-up care 363
  - glia alterations 332
  - mortality 217
  - noradrenergic system
    - neurochemistry 326–328
  - norepinephrine
    - neurochemistry 326
    - role 332, 333
    - signaling manipulation 328–331
  - older adults 184, 188
  - panic attacks 97
  - physical illness 201–202
  - primary care detection/management 358
  - risk factors 94–95
    - schizophrenia 102
  - substance use disorders 119
  - suicide ideation 97
  - suicide risk in epilepsy 132
  - treatment 362–363
    - youths 155
  - tyrosine hydroxylase role 326–327
  - see also* antidepressants; major depressive disorder (MDD)
- depression-executive dysfunction syndrome 184
- DerSimonian and Laird method 78
- developmental group therapy (DGT) 155
- diacylglycerol (DAG) 344
- Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5)* 109–110, 114–115
- dialectical behavioral therapy (DBT) 363
  - borderline personality disorder 112
  - psychosocial approaches to reduce suicidal behavior 268, 272
- differential effects 83–84
- disability
  - older adults 185–187
  - schizophrenia 104
- disinhibition 114
- divalproex 222
- DNA
  - chromatin 289
  - epigenetics 288–289
- DNA methylation 289, 291
  - genome-wide alteration by early life stress 296–297
- DNMT1 expression 295
- documentation, suicide risk
  - assessment 253
- domestic violence safety planning 370
- dopaminergic system, substance use disorders 119
- dorsal raphe nucleus 317
  - neuroanatomy 318–319, 319
  - serotonin indices alterations in
    - depressed suicides 320
  - TPH2 levels 321
  - early life stress 322
- drinking water, lithium in 221–222
- duloxetine 241
- early life, brain regulation 288–290
- early life adversity
  - AVP gene 292–293
  - burden 288–290
  - cortisol levels 290
  - CRF gene 293
  - DNA methylation genome-wide alteration 296–297
  - HPA axis alterations 290–291
- early life stress (ELS)
  - schizophrenia 103
  - TPH2 levels 321
- eating disorder(s) 123–127
  - acquired capability for suicide 125–127
  - interpersonal theory of suicide 125–127
  - low belongingness 126–127
  - perceived burdensomeness 126
  - postmortem studies 125
  - psychological autopsy 125
  - social impairment 127
  - suicidal ideation 123–124
  - suicide attempts
    - fatal 124–125
    - non-fatal 124
- eating disorder not otherwise specified (EDNOS) 123
  - fatal suicide attempts 125
- ecological momentary assessment (EMA) 44
- educational attainment, schizophrenia patients 104
- emergency room 244–254
  - focus of care 247–250
- medical clearance and referral process 249–250
- referral
  - to mental health specialists 249–250
  - to outpatient mental health treatment 366
- screening
  - indicated 247
  - selective 247–248
  - universal 248
- suicide risk assessment 247–249, 252–253, 253
  - capacity 252
  - collateral information 253
  - confidentiality 253
  - documentation 253
  - intoxication and capacity 252
  - involuntary treatment 252
  - standard of care 252
  - voluntary treatment 252
- suicide risk identification 247–248
- terminology 244–247
- emotion regulation 68
- empirical Bayes screening (EBS) 75, 78
- Enlightenment 9–10
- epidemiology of suicide 13–16, 93–94
  - adolescents 151–152
  - anxiety 93–98
  - armed forces 191–193
  - children 151–152
  - college students 173–174
  - depression 93–98
  - indigenous populations 159
  - pathophysiology 95–97
  - rates
    - by country 14–15
    - worldwide 64
  - USA 13
  - worldwide 13–14
    - rate 64
- epigenetic modification 96
- epigenetics 288–297
  - AVP gene 292–293
  - BDNF gene 293–294
- components
  - in animal models of stress-induced depression 298
  - in suicide 297
- CRF gene 293
- definition 288–289
- GABAergic system 295
- genome-wide DNA methylation alteration by early life stress 296–297
- GR gene 293–294
- histone modifications 289
- polyamines 296
- serotonergic system 296
- TrkB receptor gene 294–295

## Index

- epilepsy 130–135
  - alternative psychopathology 132–133
  - completed suicide attempts 130
  - complex relationship with suicide 131–134
    - bidirectionality 131
  - epidemiology of suicide 130
  - GABA activity 131–132
  - glutamate activity 131–132
  - HPAA axis dysfunction 132
  - iatrogenic processes 132–133
  - identification of patients at risk of suicide 134–135
  - non-fatal suicide attempts 130
  - norepinephrine 131
  - pathogenic mechanisms 131–132
  - psychiatric risk factors 132
  - serotonergic system 131
  - suicidal ideation 130
  - suicide risk 132–134, 203
  - surgery and suicide risk 134
  - syndrome type 132
    - see also* antiepileptic drugs (AEDs)
- ERK1/2-MAP kinase signaling 352–353
- escitalopram 239
- ethnicity 62–64
  - children/young people 151
- European history
  - Enlightenment 9–10
  - Middle Ages 6–7
  - nineteenth century 10–11
  - Renaissance 7–9
- extrapyramidal side effects, antipsychotic medication 230
- family history
  - schizophrenia 103
  - youths 154
- family therapy 269–270
  - attachment-based 156
- fictional suicide accounts 54
- firearms 362
- fluoxetine 238–239
- Food and Drug Administration (FDA)
  - black box warning on antidepressants 237–238, 363
  - clozapine approval for schizophrenia treatment 231–232
- forced normalization 132–133
- fronto-striatal network, major depressive disorder association 307–309
- functional magnetic resonance imaging (fMRI) 309–311
  - structural 307–309, 313
- G protein 343, 344–346, 345
  - function 346
  - subunit classification 345–346
- GABA, epilepsy 131–132
- GABAergic system 295
- GAD1 expression 295
- gay, lesbian, bisexual, and transgender (GLBT) people 176–177
- genetic factors 95, 96
- genome-wide association studies (GWAS)
  - approaches to genetic associations 278–279
  - calcium channel genes 284
  - classical SNP-by-SNP 278–279, 283–284
  - errors 278
  - gene-wide 279
  - goals 277
  - pathway/network 279
  - suicidal behaviors 277–284
  - suicidality measures 279–283
  - technology 277
  - usage 277–278
- glia 331–332
- glucocorticoid receptor (GR) 290–291, 336, 340
  - early life adversity in epigenetic regulation 291–292
- glucocorticoid receptor 1<sub>F</sub> (GR 1<sub>F</sub>)
  - hippocampal expression 291
  - promoter methylation 291
- glucocorticoid receptor (*GR*) gene 291–292
- glutamate 331
  - epilepsy 131–132
  - noradrenergic system role 331
- glycogen synthase kinase 3 (GSK3) signaling pathway 322
- grief
  - Bowlby's ideas 67–68
  - complicated 67, 68–69
    - identification/treatment 71, 71
  - definitions 66–67
  - framework 67–68
  - integrated 66–67
  - model 69
  - mourning process 67
  - suicide bereavement 69–70
  - suicide-related 66–72
  - uniqueness of response 67, 68
- guanine deaminase (*GDA*) gene 282
- guanosine diphosphate (GDP) 344
- guanosine triphosphate (GTP) 344
- hallucinations, command 102
- healing
  - model 69
  - process 68
- Hebraism 3, 5
- highly active antiretroviral therapy (HAART) 204
- high-risk cognitive states 42–48
  - attentional fixation 44
  - cognitive rigidity 47
  - homicidal ideation 46–47
- hopelessness 44–45
- implicit associations 47
- memory 47
- perfectionism 46
- problem solving deficits 45–46
- research recommendations 47
- suicide ideation 42–44
- hippocampus
  - DNMT1 expression 295
  - GAD1 expression 295
  - glucocorticoid receptor expression 291
  - GR 1<sub>F</sub> expression 291
  - NGF1-A levels 291
  - serotonin turnover 290
  - volume loss in early life adversity 290
- histone modifications 289
- historical aspects 3–11
  - ancient Egypt 3
  - ancient Greece 3, 4
  - ancient Rome 4
  - Christianity 3, 5
  - Enlightenment 9–10
  - Hebraism 3, 5
  - Islam 3, 5
  - Middle Ages 6–7
  - nineteenth century 10–11
  - Renaissance 7–9
- historical trauma, indigenous populations 160–161
- histrionic personality disorder (HPD) 112
- HIV/AIDS
  - stigma 203
  - suicide risk 203–204
- homicidal ideation 46–47
- hopelessness 44–45
  - risk factor in schizophrenia 102
- substance use disorders 118
- hospitalization
  - psychosocial approaches to reduce suicidal behavior 271
  - suicide risk 362
- Huntington's disease 202–203
- 5-hydroxyindoleacetic acid (5-HIAA) 96
  - levels
    - in depressed suicides 321
    - in substance use disorders 119
  - suicide involvement 319–320
- 5-hydroxytryptamine (5-HT)
  - brain levels in psychological autopsy 317–322
  - brainstem levels 323
  - dorsal raphe nucleus alterations in depressed suicides 320
  - levels in depressed suicides 321
  - suicide involvement 319–320
  - synthesis 317
- 5-hydroxytryptamine 1A (5-HT<sub>1A</sub>) 320
- 5-hydroxytryptamine 2A (5-HT<sub>2A</sub>) 296



## Index

- 5-hydroxytryptamine 2A (5-HT<sub>2A</sub>) receptor 312
- 5-hydroxytryptamine (5-HT) receptors 312
- 5-hydroxytryptamine transporter (5-HTT) 320
- molecular neuroimaging 311–312, 311
- hypothalamic–pituitary–adrenal (HPA) axis 336–341
- alterations with early life adversity 290–291
- animal models 290–291
- CRF action on 338
- CRF-BP role 339–340
- dysfunction 95–96, 337–338
- epilepsy 132
- perinatal period 147
- regulation 337, 337
- stress effects 336
- stress regulation 290
- hypothalamus, paraventricular nucleus 292–293
- imipramine, BDNF transcription 294
- implicit associations 47
- impulsivity 114–115
- college students 177
- substance use disorders 118
- indigenous populations 159–164
- cultural factors 160, 161
- epidemiology of suicide 159
- historical trauma 160–161
- interventions 161
- community-engaged approaches 162–163
- indigenous approaches 161–162
- strengths-based approaches 161
- prevention strategies 162
- protective factors 160–161
- researcher roles 162–163
- suicide attempts 159
- suicide risk factors 160–161
- youths 159–160, 161
- inflammatory markers, perinatal period 147
- institutional liability, legal cases 178
- integrated cognitive behavioral therapy (iCBT) 156
- intent to act 27
- suicide ideation 42
- intent to die 19–21
- interpersonal theory of suicide 256–257
- eating disorders 125–127
- interpersonal therapy (IPT) 269
- intoxication, suicide risk assessment and capacity 252
- intracellular signaling pathways 344
- adenyl cyclase-cAMP 344
- phosphoinositide 344
- Islam 3, 5
- ketamine 331
- Latin America, epidemiology 14
- legal issues, suicide risk assessment 252–253
- lethal means restriction 361–362, 369
- liability, legal cases 178
- life neglect, environmental suicide risk factor 321–322
- life stresses
- severe 89–90
- see also* early life stress (ELS); stress
- lithium
- bipolar disorder treatment 217–225
- evidence for 218–219
- patient monitoring 224
- study limitations 224
- suicide risk meta-analysis 219, 220
- borderline personality disorder treatment 221
- drinking water 221–222
- mechanism of action 223
- personality disorder treatment 221
- prevention of suicide 363
- psychopathological condition treatment 221
- serotonergic system effects 223–224
- locus coeruleus (LC) 325
- alpha<sub>2</sub> adrenergic receptors 328
- antidepressant actions 332–333
- norepinephrine transporter 326–327
- tyrosine hydroxylase activity 326–327
- logistic regression
- mixed-effects 78–79
- person–time models 81–83
- low serotonin syndrome 119
- magnetic resonance imaging (MRI)
- see* functional magnetic resonance imaging (fMRI)
- major depressive disorder (MDD)
- fMRI 307–309, 311
- 5-HTT alterations 311, 311
- treatment 362
- Mantel–Haenszel (MH) method 78
- MAP kinases 353
- marginal structural models 84
- maternal suicide 139–147
- MeCP2 protein 292–293
- media 378–381
- audience reception studies 378, 379
- content analysis studies 378–379
- guidelines 380
- influence studies 378–381
- mitigation of effects 58
- news production research 378, 379–380
- newspaper reporting 53
- quality and accuracy studies 378, 379
- research studies 378
- suicide cluster effects 53–54, 56–57
- suicide contagion effects 53–54, 58, 380–381
- suicide survivors 69–70
- median raphe nucleus 317
- anatomy 319
- neuroanatomy 318, 319
- medical claims data 80–84
- case–control studies 80
- memory 47
- mental health care
- armed forces 197
- requirements in correctional facilities 209
- surveillance in armed forces 193
- mental health specialists
- referral to 249–250
- medical clearance/process 249–250
- suicide risk assessment/management 250–252
- mental illness
- armed forces 194, 196
- college students 173–174
- cultural difference 62–63
- older adults 184–185
- perinatal period 139–141, 147
- primary care detection/management 357–358
- surveillance in armed forces 193
- youths 153–154
- metabolic syndrome, schizophrenia 104–105
- method of suicide
- armed forces 192
- children 151–152, 153
- correctional facilities 210
- perinatal period 141
- restriction of access to 361–362, 369
- youths 151–152, 153
- Mexicans/Mexican-Americans, epidemiology 14
- Middle Ages 6–7
- mineralocorticoid receptor (MR) 336, 340
- mirtazapine 241, 330
- molecular neuroimaging 311–312
- monoamine oxidase(s) (MAO) 327
- monoamine oxidase inhibitors (MAOIs) 242, 329
- mood disorders
- neuronal pathway plasticity alteration 343
- primary care provider recognition/diagnosis 357–358
- screening 358, 359, 360
- see also* named disorders
- mourning 67
- multiple sclerosis 203
- myristoylated alanine-rich C kinase substrate (MARCKS) 347–348

## Index

- narcissistic personality disorder (NPD) 112
- native populations *see* indigenous populations
- nerve growth factor 1-A (NGF1-A) 290, 291
- hippocampus levels 291
- neuroimaging 307–314
- fMRI 309–311
- structural 307–309, 313
- modalities 307
- molecular 311–312
- neuronal pathways, plasticity alteration 343
- neuroplasticity 96
- neuroprotection 96
- neuropsychological function 96
- neurotransmitter receptors 343
- news production research 378, 379–380
- newspaper reporting, suicide cluster effects 53
- nineteenth century history 10–11
- no-harm, no-suicide contract 362
- see also* safety contract
- non-suicidal self-injury (NSSI) 111
- noradrenergic synapse 325
- noradrenergic system 325–334
- adrenergic receptors 327–328
- behavior modification 326
- future research 331–332
- glia 331–332
- glutamate 331
- neurochemistry 326–328
- norepinephrine signaling manipulation 328–331
- norepinephrine 325–326
- alpha<sub>2</sub> adrenergic receptor actions 328
- depression role 332, 333
- epilepsy 131
- monoamine oxidase effects 327
- neurochemistry 326
- signaling manipulation 328–331
- stress role 333
- synthesis 325
- tyrosine hydroxylase effects 326–327
- norepinephrine transporter 327, 330
- no-suicide contracts 367, 372–373
- obesity
- schizophrenia 105
- suicide risk 204
- observational data, drawing causal inferences from 83–84
- obsessive-compulsive personality disorder (OCPD) 113
- olanzapine 330
- schizophrenia treatment 232
- older adults 182–189
- comorbidity 185
- dementia 184–185
- depression 184, 188
- disability 185–187
- mental illness 184–185
- physical illness 185–187, 204
- prevention of suicide 183, 184, 187–185, 188
- interventions 186
- multi-level intervention 188–189
- social connectedness 187–188
- suicidal behaviors 182–183
- suicidal ideation 182–183, 206
- suicide rate 182, 183
- opioid deficit in non-suicidal self-injury 111
- osteoporosis 202
- outpatient referral 367
- outreach interventions
- contact 270–271
- intensive 270
- psychosocial approaches to reduce suicidal behavior 270–271
- overseas deployment, armed forces 195
- p75<sup>NTR</sup> signaling 351–352
- panic disorder 94, 97
- paraventricular nucleus (PVN) of hypothalamus 292–293
- paroxetine 240
- passion 3
- pathophysiology of suicide 95–97
- perfectionism 46
- personality disorders 109–115
- classification 109
- Cluster A 113
- Cluster B 110–113
- Cluster C 113
- lithium treatment 221
- longitudinal studies 113–114
- new models 109–110, 114–115
- personality traits, emerging models 114–115
- person–time logistic regression models 81–83
- pharmaceutical drugs 74
- access to for lethal overdose 362
- between-subject designs 81
- coherence 84
- cohort studies 80
- cumulative sum method 75
- differential effects 83–84
- drawing causal inferences from observational data 83–84
- ecological methods for rare adverse events 76–77
- empirical Bayes screening 75
- history for psychological autopsy 318
- marginal structural models 84
- medical claims data 80–84
- meta-analysis of RCTs 77–80
- norepinephrine signaling manipulation 328–331
- novel statistical strategies 81–83
- perinatal period 146
- person–time logistic regression models 81–83
- Poisson method 75
- post-marketing drug surveillance 80–84
- propensity score matching 83
- proportional reporting ratio 74–75
- psychotherapy combination 363
- psychotropic in perinatal period 146
- spontaneous reports 74–76
- SSRIs/SNRIs 75–76
- suicidality in schizophrenia 105–106, 230
- suicide rate 87
- within-subject designs 81
- see also* named drugs and drug types
- phosphoinositide (PI) signaling system 344, 345
- phosphoinositide-specific phospholipase C (PI-PLC) 344, 347
- physical illness 201–206
- cancer 204–205
- depression 201–202
- HIV/AIDS 203–204
- Huntington's disease 202–203
- life-threatening 201
- multiple sclerosis 203
- obesity 204
- older adults 185–187, 204
- screening 205–206
- suicide risk factors 201–202
- traumatic spinal cord/brain injuries 203
- see also* epilepsy
- Poisson method 75
- polyamines 296
- positron emission tomography (PET) 311–312
- post-marketing drug surveillance 80–84
- postpartum depression 139
- postpartum period 139–147
- age at suicidal behavior 144
- breastfeeding 144–145
- completed suicide attempts 140
- epidemiology of mental illness 139–141
- gonadal steroid role in mental illness 147
- HPA axis changes 147
- inflammatory markers 147
- interpersonal relationships 144
- marital status 144
- psychiatric history 143–144
- screening for suicide risk 145–146
- serotonergic system 147
- social support 144

Cambridge University Press

978-1-107-03323-8 - A Concise Guide to Understanding Suicide: Epidemiology, Pathophysiology, and Prevention

Edited by Stephen H. Koslow, Pedro Ruiz and Charles B. Nemeroff

Index

[More information](#)

## Index

- postpartum period (cont.)
  - suicidal ideation 139–140
  - suicide behaviors 141
  - suicide methods 141
  - suicide risk 139–141
  - suicide risk factors 143–145
  - Toxoplasma gondii* infection 144
- post-traumatic stress disorder (PTSD) 63
  - armed forces 191–194
  - rat model 294
- prefrontal cortex, major depressive disorder association 308
- pregnancy 139–147
  - age at suicidal behavior 144
  - completed suicide attempts 140
  - epidemiology of mental illness 139–141
  - gonadal steroid role in mental illness 147
  - HPA axis changes 147
  - inflammatory markers 147
  - interpersonal relationships 144
  - marital status 144
  - prevention of suicide 145–146
  - psychiatric history 143–144
  - screening for suicide risk 145–146
  - serotonergic system 147
  - social support 144
  - suicidal ideation 139–140
  - suicide behaviors 141
  - suicide methods 141
  - suicide risk 139–141
  - suicide risk factors 143–145
  - Toxoplasma gondii* infection 144
  - unplanned 144
- prevention of suicide 97
  - antidepressants 362–363
  - armed forces 195–196
  - bipolar disorder treatment 362–363
  - college students 177–180
  - community-engaged approaches 163
    - indigenous populations 162–163
  - definitions of types 247
  - depression treatment 362–363
  - indigenous populations 162
    - community-engaged approaches 162–163
  - lethal means restriction 361–362
  - mood disorder recognition/
    - diagnosis by primary care provider 357–358
  - older adults 183, 184, 187–185, 188
    - multi-level intervention 188–189
  - perinatal period 145–146
  - psychotherapy 363
  - public education 364
  - safety contract 362, 372–376
    - advantages 374–375
    - alternatives 375–376
  - history 372–373
    - reasons for avoiding 375
    - spread of 373
    - unintended consequences 373–374
  - safety planning for suicidal behavior 366–371
  - screening for suicidality 358
  - strategies to improve 357–364
  - substance use disorders 120
  - suicidal patient management 362
  - suicidality evaluation 358–361
  - suicide contagion 58
- primary care
  - mood disorder recognition/diagnosis 357–358
  - psychiatric training 357
  - screening 205
  - suicidal ideation 35
    - interventions 205
- problem orientation 45
- problem solving deficits 45–46, 257
- problem solving skills 45
  - instruments 45–46
- problem solving therapy (PST) 257–268
- pro-opiomelanocortin (POMC) 290
- propensity score matching 83
- proportional reporting ratio (PRR) 74–75
- protein kinase A (PKA) 322, 344, 348–349
  - cAMP binding 348
  - subtypes 348, 349
- protein kinase C (PKC) 344, 347–348
  - classes 347
  - isozyme expression 347
- psychiatric diagnosis 93
  - suicide risk 18, 94
- psychiatric disorders
  - youths 153–154
  - see also* mental illness
- psychiatric training, primary care 357
- psychoanalytic therapy 270
- psychological autopsy
  - brain serotonin levels 317–322
  - importance 317–318
  - neuropathological examination 318
  - pharmaceutical drug history 318
  - toxicological screen 318
  - see also* tryptophan hydroxylase (TPH2)
- psychopathological conditions
  - lithium treatment 221
  - suicide risk 357–358
- psychosocial approaches to reduce suicidal behavior 256–273
  - adherence 273
  - cognitive behavioral techniques 257–269
  - cognitive behavioral therapy 257, 271
  - general 268–269
- comparison conditions 272
- dependent variables 272
- dialectical behavioral therapy 268, 272
- family therapy 269–270
- generalizability 272
- hospitalization 271
- interpersonal therapy 269
- outcomes targeted 257
- outreach interventions 270–271
- problem solving therapy 257–268
- psychoanalytic therapy 270
- randomized controlled trials 257–272
- research studies 257
- self-injury history 272–273
- study duration 273
- psychotherapy
  - borderline personality disorder 112
  - pharmaceutical drug combination 363
  - prevention of suicide 363
  - schizophrenia 106
- psychotropic medication, perinatal period 146
- public education, prevention of suicide 364
- public health impact 17
- quality and accuracy studies of media influence 378, 379
- quetiapine 330
- randomized controlled trials (RCTs)
  - cognitive behavioral therapy 257–269, 271
  - family therapy 269–270
  - hospitalization 271
  - interpersonal therapy 269
  - meta-analysis 77–80
  - outreach interventions 270–271
  - psychoanalytic therapy 270
  - psychosocial approaches to reduce suicidal behavior 257–272
  - research synthesis 79–80
  - suicidal thoughts/behaviors 258
- rate multipliers 75
- reason 3
- reason for living, college students 177
- receptor signaling 343–353
  - adenyl cyclase-cAMP 344, 345
  - BDNF 350–351, 353
  - CREB 349–350
  - ERK1/2-MAP kinase 352–353
  - G proteins 344–346, 345
  - p75<sup>NTR</sup> 351–352
  - phosphoinositide 344, 345
  - PI-PLC 347
  - PKA 348–349
  - PKC 347
  - TrkB 351, 353
  - Renaissance 7–9



## Index

- restricting subtype anorexia nervosa (RAN) 123
- riluzole 332
- risperidone 232
- safety contract 362, 372–376
- advantages 374–375
  - alternatives 375–376
  - coercion 374
  - ethics 374
  - history 372–373
  - nurse personal responsibility 374
  - outcomes 374
  - spread of 373
- safety planning 366–371
- application 370
  - collaborative 369–370
  - crisis in substance use disorders 120
  - domestic violence 370
  - need for immediate interventions 366–367
  - no-suicide contracts 367
  - other populations 370
- safety planning intervention (SPI) 366, 367–368
- applications 370
  - basics 368–370
  - completion 368
  - coping strategies 368
  - development 368
  - family/friends support 369
  - lethal means restriction 369
  - professional agencies 369
  - risk assessment 368
  - social strategies 369
- schizophrenia 63, 101–107
- clozapine treatment 229
    - agranulocytosis monitoring 231, 232, 233
    - dosage 234
    - drug interactions 234
    - FDA approval 231–232
    - outcomes 233
    - smoking cessation 234
    - suicide risk 230–232
    - suicide risk reduction guidelines 233–234
    - underutilization 232–233
  - cognitive behavioral therapy 106
  - cognitive impairment 103–104
  - command hallucinations 102
  - comorbid substance abuse 103
  - demographic risk factors 102
  - depression 102
  - disability 104
  - early life stress 103
  - educational attainment 103–104
  - family history 103
  - hopelessness 102
  - metabolic syndrome 104–105
  - obesity 105
  - olanzapine treatment 232
  - pharmaceutical treatment for suicidality 105–106, 230
  - prediction of suicide 102–103, 105
  - premorbid functioning 104
  - protective factors 105
  - psychotherapy 106
  - risperidone treatment 232
  - suicide attempt methods 103
  - suicide rate 101–102, 230
  - suicide risk 229–230
    - assessment 102–103
    - clozapine treatment 230–232
  - suicide risk factors 102, 106, 229–230
  - treatment 221
  - see also* antipsychotic medication
- schizotypal personality disorder (StPD) 113
- screening 17–18, 19, 27–28, 58
- armed services 193
  - college students 174
  - correctional facilities 213
  - indicated 247
  - mood disorders 358, 359, 360
  - perinatal period 145–146
  - physical illness 205–206
  - primary care 205
  - protocol 35n
  - selective 247–248
  - suicidal ideation 35, 43, 358
  - suicidality 358
  - suicide risk 17–18, 19, 27–28, 58
    - college students 174, 179
    - perinatal period 145–146
    - protocol 35n
    - universal 248
- screening instruments 18, 19, 35–36, 248–249
- administration methods 27–28
  - brief administration time 27
  - clinical utility 27–28
  - false negatives 36
  - formation of delivery 27
  - generalizability 29
  - intent to die 19–21
  - multiple sources of information 27
  - positive scores 36
  - problem solving skills 45–46
  - risk factors 22
  - suicidal ideation 35, 43, 358
  - suicide risk assessment 35–36
  - training level 28
  - triage capacity 28
- selective serotonin reuptake inhibitors (SSRIs) 75–76, 238–240
- non-proportional hazards for suicide attempts 82
  - person–time logistic regression models 82–83
  - prevention of suicide 362–363
  - suicide rate 77, 87
- self-directed violence 20, 244
- classification 245
- self-injury, history of 272–273
- self-stigmatization 69
- serotonergic system 96
- epigenetics 296
  - epilepsy 131
  - hippocampus 290
  - lithium effects 223–224
  - molecular neuroimaging 311–312
  - perinatal period 147
  - substance use disorders 119
  - see also* 5-hydroxytryptamine (5-HT)
- serotonin norepinephrine reuptake inhibitors (SNRIs) 75–76, 240–241
- mechanism of action 330
  - norepinephrine signaling manipulation 329–330
- serotonin transporter (SERT)
- see* 5-hydroxytryptamine transporter (5-HTT)
- sertraline 240
- signs 87–91
- anxiety 90
  - severe life stresses 89–90
  - see also* suicide risk
- single nucleotide polymorphisms (SNPs) 278–279, 284
- classical SNP-by-SNP GWAS 278–279, 283–284
  - gene-wide GWAS 279
  - treatment-emergent suicidal ideation GWAS 279–282
- single photon emission computed tomography (SPECT) 311–312
- small area estimation 76
- social connectedness, older adults 187–188
- social impairment, eating disorders 127
- social learning theory, suicide contagion 57
- social support, armed forces 195
- spinal cord injuries 203
- statistics 74–84
- Bayes estimate of suicide rate 75, 78
  - between-subject designs 81
  - case-control studies 80
  - coherence 84
  - cohort studies 80
  - cumulative sum method 75
  - DerSimonian and Laird method 78
  - differential effects 83–84
  - drawing causal inferences from observational data 83–84
  - ecological methods for rare adverse events 76–77
  - empirical Bayes screening 75

## Index

- statistics (cont.)
  - Mantel-Haenszel method 78
  - marginal structural models 84
  - medical claims data 80–84
  - meta-analysis of RCTs 77–80
  - mixed-effects logistic regression 78–79
  - non-proportional hazards for suicide attempts 82
  - novel strategies 81–83
  - person–time logistic regression models 81–83
  - Poisson method 75
  - propensity score matching 83
  - proportional reporting ratio 74–75
  - rate multipliers 75
  - research synthesis 79–80
  - small area estimation 76
  - statistical properties comparison 79
  - suicide cluster techniques 52
  - within-subject designs 81
- steroids, gonadal 147
- stigma 69
  - armed forces 196–197
  - HIV/AIDS 203
- strengths-based approaches for indigenous populations 161
- stress 95, 96
  - armed forces 194–195
  - early life stress
    - genome-wide DNA methylation alteration 296–297
    - schizophrenia 103
  - HPA axis effects 336
  - incarceration in correctional facility 210
  - norepinephrine effects 326
  - role 333
  - regulation
    - by HPA system 290
    - by polyamines 296
  - severe life stresses 89–90
  - see also* early life adversity
- stroke, suicide risk 202
- substance abuse 62
  - college students 175
  - comorbid with schizophrenia 103
- substance use disorders (SUDs) 117–120
  - adolescents 118
  - assessment 119–120
  - clinical characteristics 119
  - crisis safety planning 120
  - depression 119
  - dopaminergic system dysfunction 119
  - hopelessness 118
  - impulsivity 118
  - neurobiologic connections 118–119
  - prevention 120
  - serotonin system disorders 119
- suicide prevalence 117
- suicide risk 117–118
- treatment 120
- suicidal behavior
  - adolescents 240–241, 241
  - bullying 167–168
  - children 240–241, 241
  - college students 173
  - disclosure of intent 34
  - fMRI 310
  - genetics 277–278
  - genome-wide association studies 277–284
    - suicidality measure 282–283
  - homicidal ideation 46–47
  - older adults 182–183
  - prevention 366–371
  - psychosocial approaches to reduce 256–273
  - randomized controlled trials 258
  - range 19–21
  - suicidal ideation
    - association 42–43
    - distinction 21–27
- suicidal crisis
  - crisis response plan 367
  - dealing with 369
  - interventions 370
- suicidal ideation
  - active 35
  - ambivalent state 43–44
  - antidepressants 238, 239
  - armed forces 191
  - behaviors 18–21
  - bullying 166, 167–168, 169
  - cancer 205
  - citalopram 239
  - construct 42
  - denial 34–35, 88–89
  - depressed patients 97
  - determining presence 34
  - eating disorders 123–124
  - ecological momentary assessment 44
  - emergency department 35
  - epilepsy 130
  - fluoxetine 239
  - fMRI 310–311
  - guide to better assessment 36–37
  - high-risk cognitive states 42–44
  - intent to act 27, 42
  - measures 43
  - older adults 44, 182–183, 206
  - passive 35
  - perinatal period 139–140
  - predictions 34–35
  - prevalence 34, 42
  - primary care 35
  - interventions 205
  - progression to attempt 247
  - randomized controlled trials 258
- screening instruments 35, 43, 358
- suicidal behavior
  - association 42–43
  - distinction 21–27
- suicide cluster effects 54
- suicide risk assessment 33–34, 43
- treatment-emergent 279–282
- young people 152–153
- suicidal intent 244
- suicidal patients, management 362
- suicidal phenomena, definitions 19
- suicidality
  - evaluation 358–361
  - screening 358
- suicide
  - definition 67
  - see also* method of suicide; prevention of suicide
- Suicide Assessment Follow-up Engagement Treatment (SAFE VET) 370
- suicide attempts
  - armed forces 191
  - bipolar disorder 217
  - bullying 166, 167–168
  - fatal
    - eating disorders 124–125
    - epilepsy 130
    - perinatal period 140
  - follow-up care 363–364
  - indigenous populations 159
  - methods in schizophrenia 103
  - non-fatal
    - eating disorders 124
    - epilepsy 130
  - non-proportional hazards 82
  - older adults 182–184
- suicide clusters 52–55, 56–57
  - contextual effects 53
  - direct exposure to another's suicide 55–56
  - fiction impact 54
  - geographical 52–53
  - media effects 53–54, 56–57
  - risk factors 52–53, 56–57
  - space-time 54–55
  - statistical techniques 52
  - suicide ideation media report effects 54
  - temporal 53–54
  - types 52–55
  - youths/young adults 55
- suicide contagion 52, 55–56, 57–58
- approach–avoidance conflict 57–58
- mechanisms 57–58
- media effects 53–54, 58, 380–381
- mitigation 58
- risk factors 57

Cambridge University Press

978-1-107-03323-8 - A Concise Guide to Understanding Suicide: Epidemiology, Pathophysiology, and Prevention

Edited by Stephen H. Koslow, Pedro Ruiz and Charles B. Nemeroff

Index

[More information](#)

## Index

- social learning theory 57
- strategies to prevent 58
- suicide prevention contract 362
- suicide rate
  - antipsychotic medication 87, 222
  - armed forces 191, 192
  - Bayes estimate 75, 78
  - bipolar disorder 217
  - children/youths 79, 152, 152, 153
  - college students 173
  - correctional facilities 209–212
  - older adults 182, 183
  - schizophrenia 101–102, 230
  - SSRI dose in Japan 77
  - worldwide 64, 64
- suicide risk
  - acute 87–88, 91, 251
  - antidepressants 97, 240–241
    - children/adolescents 240–241
  - antiepileptic drugs 133–134, 203
  - anxiety 90
  - bipolar disorder 219
  - cancer 204–205
  - chronic 87–88, 91
  - clozapine treatment for
    - schizophrenia 230–232
  - correctional facilities
    - monitoring 213–214
    - profile in 212–213
    - screening 213
  - current factors 89–90
  - dementia 202–203
  - demographic predictors 101–102
  - epilepsy-related factors 132–134, 203
  - high 252
  - HIV/AIDS 203–204
  - hopeless beliefs 45
  - hospitalization 362
  - Huntington's disease 202–203
  - identification 17–27, 247–248
  - imminent 37, 38
  - intent to die 19–21
  - level 37–38, 39, 251
    - estimation 250–252
  - low 251
  - management by mental health
    - specialists 250–252
  - moderate 251–252
  - monitoring in correctional facilities
    - 213–214
  - multiple sclerosis 203
  - obesity 204
  - paroxetine 240
  - perinatal period 139–141, 143–145
  - post-discharge from hospital 89
  - psychiatric diagnosis 18
  - reliability of judgment 38
  - scales 38
  - schizophrenia 229–230
    - clozapine treatment 230–232
  - screening 17–18, 19, 27–28, 58
    - correctional facilities 213
    - perinatal period 145–146
    - protocol 35n
  - severe life stresses 89–90
  - spinal cord injuries 203
  - substance use disorders 117–118
  - traumatic brain injury 203
  - venlafaxine 240–241
  - warning signs 38
- suicide risk assessment (SRA) 33–39
  - acute risk 87–88, 91
  - capacity 252
  - chronic risk 87–88, 91
  - clinical data 91
  - collateral information 253
  - college students 178, 179
  - competent 87
  - components 33
  - confidentiality 253
  - documentation 253
  - emergency room 247–249, 252–253, 253
  - epilepsy 134–135
  - full 89
  - intoxication and capacity 252
  - involuntary treatment 252
  - legal considerations 252–253
  - mental health specialists 250–252
  - new methods 91
  - notation 89
  - outpatient referral 367
  - patient management 362
  - problems in 88–89
  - prospective studies 91
  - research 90–91
  - safety planning intervention 368
  - schizophrenia 102–103
  - screening protocol 35n
  - standard of care 33, 33n, 252
  - steps 33
  - suicidal ideation 33–34, 43
    - active 35
    - denial 34–35
    - determining presence 34
    - emergency department 35
    - guide to better assessment
      - 36–37
    - passive 35
    - predictions 34–35
    - primary care 35
  - timing 89
  - voluntary treatment 252
  - see also* screening; screening instruments
- suicide risk factors 94–97, 247
  - armed forces 193–195
  - bipolar disorder 95
  - bullying 166
  - children 152–155
  - college students 174–177
  - correctional facilities 209–210
  - demographic 102
  - depression 94–95
    - schizophrenia 102
  - environmental 321–322
  - epilepsy 132–134
    - psychiatric risk factors 132
  - hopelessness in schizophrenia 102
  - indigenous populations 160–161
  - instruments 22
  - physical illness 201–202
  - postpartum period 143–145
  - pregnancy 143–145
  - problem solving deficits 45–46, 257
  - psychopathological conditions
    - 357–358
  - schizophrenia 102, 106, 229–230
    - demographic risk factors 102
    - hopelessness in 102
  - screening instruments 22
  - suicide clusters 52–53, 56–57
  - suicide contagion 57
  - treatment targets 256–257
  - youths 152–155
- suicide risk formulation (SRF) 33, 37
  - clinical judgment 39
  - models 38–39
  - outcomes 38–39
- suicide survivors
  - definition 67
  - media relationship 69–70
- suicide warning signs 247
- symptoms 87–91
  - anxiety 90
  - control 97
  - severe life stresses 89–90
  - see also* suicide risk
- temporal lobe epilepsy 131, 132
- temporal lobectomy 134
- toxicological screen, psychological
  - autopsy 318
- Toxoplasma gondii* during
  - pregnancy 144
- traumatic brain injury (TBI)
  - armed forces 194
  - suicide risk 203
- treatment-emergent suicidal ideation
  - (TESI) 279–282
- tricyclic antidepressants 241–242
  - norepinephrine signaling
    - manipulation 329
- TrkB signaling 351, 353
- tropomyosin-related kinase B (*TrkB*)
  - receptor gene 294–295
- tryptophan hydroxylase (TPH2) 317, 320–321
  - environmental factors affecting
    - 321–322

Index

tryptophan hydroxylase (TPH2) (cont.) regulation 322 serotonin dysregulation in brainstem 323 tryptophan hydroxylase (TPH) isoforms 321, 322 tyrosine hydroxylase (TH) 326–327	victimization bullying 168–169 cyberbullying 169–170  weapons management, armed forces 197 within-subject designs 81	epidemiology of suicide 151–152 ethnicity 151 family process treatments 155–156 indigenous populations 159–160, 161 interventions 155–156 psychiatric disorders 153–154 psychological factors 154 psychosocial factors 154–155 risk factors 152–155 sex 151 social process treatment 155–156 suicidal ideation 152–153 suicide clusters 55 suicide rate 79, 152 trends in 152, 153 <i>see also</i> college students
understanding 3 unit cohesion, armed forces 195 USA, epidemiology 13  valproate 222 vasopressin (AVP) 290 vasopressin (AVP) gene 292–293 enhancer 292–293 venlafaxine 240–241	youths/young adults 151–157 age at suicide 151 borderline personality disorder 111–112 bullying 166–171 changes following black box warning 77 depression treatment 155 developmental group therapy 155	